Βέλγιο - Αγγλικά - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

noridem enterprises ltd. - cefepime dihydrochloride monohydrate 1189 mg - eq. cefepime 1000 mg - powder for solution for injection/infusion - 1 g - cefepime dihydrochloride monohydrate 1189 mg - cefepime

Βέλγιο - Αγγλικά - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

noridem enterprises ltd. - cefepime dihydrochloride monohydrate 2378 mg - eq. cefepime 2000 mg - powder for solution for injection/infusion - 2 g - cefepime dihydrochloride monohydrate 2378 mg - cefepime

Βέλγιο - Αγγλικά - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - cefepime dihydrochloride monohydrate 1,213 g - eq. cefepime 1000 mg - powder for solution for injection/infusion - 1 g - cefepime dihydrochloride monohydrate 1213 mg - cefepime

Βέλγιο - Αγγλικά - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - cefepime dihydrochloride monohydrate 2,426 g - eq. cefepime 2000 mg - powder for solution for injection/infusion - 2 g - cefepime dihydrochloride monohydrate 2426 g - cefepime

Βέλγιο - Αγγλικά - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - cefepime dihydrochloride monohydrate 1,19 g - eq. cefepime 1 g - powder for solution for injection/infusion - 1 g - cefepime dihydrochloride monohydrate 1.19 g - cefepime

Βέλγιο - Αγγλικά - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - cefepime dihydrochloride monohydrate 2,38 g - eq. cefepime 2 g - powder for solution for injection/infusion - 2 g - cefepime dihydrochloride monohydrate 2.38 g - cefepime

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

viatris limited - cefepime dihydrochloride monohydrate 1.1518 g equivalent to 1 g cefepime free base; cefepime dihydrochloride monohydrate 1.189 g equivalent to 1 g cefepime free base - powder for injection - 1 g - active: cefepime dihydrochloride monohydrate 1.1518 g equivalent to 1 g cefepime free base excipient: arginine active: cefepime dihydrochloride monohydrate 1.189 g equivalent to 1 g cefepime free base excipient: arginine - cefepime mylan is indicated in adults for the treatment of the infections listed below when caused by susceptible bacteria. · lower respiratory tract infections, including pneumonia and bronchitis. · urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections. · skin and skin structure infections. · septicaemia. · intra-abdominal infections, including peritonitis and biliary tract infections. · empiric treatment of febrile neutropenia.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

viatris limited - cefepime dihydrochloride monohydrate 2.30368 g equivalent to 2 g cefepime free base; cefepime dihydrochloride monohydrate 2.378 g equivalent to 2 g cefepime free base - powder for injection - 2 g - active: cefepime dihydrochloride monohydrate 2.30368 g equivalent to 2 g cefepime free base excipient: arginine active: cefepime dihydrochloride monohydrate 2.378 g equivalent to 2 g cefepime free base excipient: arginine - cefepime mylan is indicated in adults for the treatment of the infections listed below when caused by susceptible bacteria. · lower respiratory tract infections, including pneumonia and bronchitis. · urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections. · skin and skin structure infections. · septicaemia. · intra-abdominal infections, including peritonitis and biliary tract infections. · empiric treatment of febrile neutropenia.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

viatris limited - cefepime dihydrochloride monohydrate 575.9mg equivalent to 500 mg cefepime free base;   - powder for injection - 500 mg - active: cefepime dihydrochloride monohydrate 575.9mg equivalent to 500 mg cefepime free base   excipient: arginine - cefepime mylan is indicated in adults for the treatment of the infections listed below when caused by susceptible bacteria. · lower respiratory tract infections, including pneumonia and bronchitis. · urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections. · skin and skin structure infections. · septicaemia. · intra-abdominal infections, including peritonitis and biliary tract infections. · empiric treatment of febrile neutropenia.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

baxter healthcare corporation - cefepime hydrochloride (unii: i8x1o0607p) (cefepime - unii:807pw4vqe3) - cefepime 1 g in 50 ml - cefepime injection is indicated for pneumonia (moderate to severe) caused by streptococcus pneumoniae, including cases associated with concurrent bacteremia, pseudomonas aeruginosa, klebsiella pneumoniae, or enterobacter species. cefepime injection as monotherapy is indicated for empiric treatment of febrile neutropenic patients. in patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. insufficient data exist to support the efficacy of cefepime monotherapy in such patients [see clinical studies (14)]. cefepime injection is indicated for uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by escherichia coli or klebsiella pneumoniae, when the infection is severe, or caused by escherichia coli, klebsiella pneumoniae, or proteus mirabilis, w